Amputation is a dreaded complication of peripheral artery disease (PAD) and diabetes
mellitus. In this issue of the Canadian Journal of Cardiology, O’Connor et al. studied secular trends in the incidence of primary lower-extremity
amputations (LEAs) associated with PAD or diabetes in the province of Québec, Canada,
between the years 2006 and 2019.
1
The investigators used large administrative databases linked together in the Quebec
Integrated Chronic Disease Surveillance System to capture episodes of LEA, subclassifying
these as major and minor, based on the highest level of amputation.
2
Amputations related to trauma, cancer, infection, congenital malformation, or venous
or lymphatic impairment were excluded. Altogether, just over 10,000 patients with
diabetes or PAD underwent primary LEA between 2006 and 2019 (n = 10,287).To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Evolution in trends of primary lower-extremity amputations associated with diabetes or peripheral artery disease from 2006 to 2019.Can J Cardiol. 2022; (xxx:xxx-xx)
- Quebec Integrated Chronic Disease Surveillance System (QICDSS), an innovative approach.Chron Dis Inj Can. 2014; 34: 226-235
- Population-based secular trends in lower-extremity amputation for diabetes and peripheral artery disease.CMAJ. 2019; 191: E955-E961
- Trends of limb amputation considering type, level, sex and age in Saskatchewan, Canada 2006-2019: an in-depth assessment.Arch Public Health. 2022; 80: 10
- Trends in diabetes-related foot disease hospitalizations and amputations in Australia, 2010 to 2019.Diabetes Res Clin Pract. 2022; 194110189
- Temporal trends in major, minor and recurrent lower extremity amputations in people with and without diabetes in Belgium from 2009 to 2018.Diabetes Res Clin Pract. 2022; 189109972
- Temporal trends in non-traumatic lower extremity amputations (LEAs) and their association with 12-month mortality in people with diabetes, 2004-2016.J Diabetes Complications. 2022; 36108221
- Editor's choice: incidence of lower limb amputations in Sweden from 2008 to 2017.Eur J Vasc Endovasc Surg. 2022; 64: 266-273
- Population-based trends in amputations and revascularizations for peripheral artery disease from 1990 to 2009.Mayo Clin Proc. 2022; 97: 919-930
- Temporal trends in incidence rates of lower extremity amputation and associated risk factors among patients using Veterans Health Administration services from 2008 to 2018.JAMA Netw Open. 2021; 4e2033953
- National and state-level trends in nontraumatic lower-extremity amputation among U.S. Medicare beneficiaries with diabetes, 2000-2017.Diabetes Care. 2020; 43: 2453-2459
- Trends of non-traumatic lower-extremity amputation and type 2 diabetes: Spain, 2001-2019.J Clin Med. 2022; 11
- Trends in incidence of total or type 2 diabetes: systematic review.BMJ. 2019; 366: l5003
- Canadian Cardiovascular Society 2022 guidelines for peripheral arterial disease.Can J Cardiol. 2022; 38: 560-587
- Efficacy and safety of antiplatelet therapies in symptomatic peripheral artery disease: a systematic review and network meta-analysis.Curr Vasc Pharmacol. 2021; 19: 542-555
- Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions.J Vasc Surg. 2007; 45 (discussion 53-4): 645-654
- Low-Density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).Circulation. 2018; 137: 338-350
- Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial.Lancet Diabetes Endocrinol. 2018; 6: 934-943
- Utilization of vasculoprotective therapy for peripheral artery disease: a systematic review and meta-analysis.Am J Med. 2018; 131: 1332-1339.e3
Article info
Publication history
Published online: December 14, 2022
Accepted:
December 10,
2022
Received:
November 30,
2022
Publication stage
In Press Journal Pre-ProofFootnotes
See article by O'Connor et al., pages xxx-xxx, of this issue
See page 2 for disclosure information.
Identification
Copyright
© 2022 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
